Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma-Reference-Cited by-同舟云学术

Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma

Published:2024-03-22 Issue:6 Volume:65 Page:736-745
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ryu Tiger Yun Kyoung¹,Jain Salvia²³⁴,Barta Stefan K.⁵⁶,Tolu Seda¹,Estrella Brian¹,Sawas Ahmed¹,Lue Jennifer K.⁷,Francescone Mark M.⁸,Pro Barbara¹,Amengual Jennifer E.¹

Affiliation:

1. Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA

2. Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA

3. Harvard Medical School, Boston, MA, USA

4. Broad Institute, Cambridge, MA, USA

5. Division of Hematology and Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

6. Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

7. Division of Hematology and Oncology, Memorial Sloan Kettering, New York, NY, USA

8. Department of Radiology, Columbia University Irving Medical Center, New York, NY, USA

Funder

Herbert Irving Scholar Program

The Esther and Oded Aboodi Lymphoma Research Fund

American Society of Hematology Research Training for Fellow Award

Conquer Cancer American Society of Clinical Oncology Young Investigator Award

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2329996

Reference39 articles.

1. Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management

2. In world health organization classification: tumours of hematopoietic and lymphoid tissues;Swerdlow SH.;IARC,2016

3. Peripheral T cell lymphomas: from the bench to the clinic

4. Updates in the Treatment of Peripheral T-Cell Lymphomas

5. Epidemiology and survival trend of adult T‐cell leukemia/lymphoma in the United States